More contraceptive choice for Australian women

Australian women will soon have access to a new form of contraceptive with the Morrison Government a new listing on the Pharmaceutical Benefits Scheme (PBS).   On March 1, Kyleena® (levonorgestrel), a long-acting reversible hormone-releasing intrauterine system (IUS) contraceptive, will be listed on the PBS for the first time, giving Australian women more choice.  …

Greater support for Australians with an intellectual disability

Australians with an intellectual disability will soon receive greater support, thanks to a Morrison Government $6.5 million investment in the Primary Care Enhancement Program.   The funding (GST exclusive) will be provided over four financial years (2020-21 to 2023-24) under the Primary Health Networks (PHN) Program, for development of the Primary Care Enhancement Program (PCEP).…

First National Action Plan for rare diseases

The Morrison Government will provide up to $3.3 million for activities to implement the first National Strategic Action Plan for Rare Diseases, which was launched today.   The Action Plan will increase awareness and promote earlier, more accurate diagnosis and treatment for around two million Australians suffering from rare diseases.   Rare diseases are having…

$2 million for vital coronavirus research

Applications have opened for the Australian Government’s $2 million grant opportunity to support research into development of a vaccine to protect against novel coronavirus (COVID-19). COVID-19 represents a significant and urgent threat to global health, with the overwhelming majority of cases in Wuhan City in China, and increasing numbers in other countries, including Australia. The…

New hope for lung cancer patients with ground-breaking treatment option to be listed on the PBS

Australians with non-small cell and small cell lung cancer or chronic obstructive pulmonary disease (COPD) will benefit from new and expanded treatment options on the Pharmaceutical Benefits Scheme (PBS) from 1 March 2020.   The Morrison Government is listing Imfinzi® (durvalumab) for the first time for the treatment of non‑small cell lung cancer for patients who…